Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2019 Earnings of $1.79 Per Share
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Analysts at Leerink Swann raised their FY2019 earnings per share (EPS) estimates for shares of Sucampo Pharmaceuticals in a research report issued on Monday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn $1.79 per share for the year, up from their prior estimate of $1.65. Leerink Swann has a “Market Perform” rating and a $15.00 price objective on the stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2020 earnings at $2.02 EPS and FY2021 earnings at $2.19 EPS.
A number of other analysts also recently issued reports on the stock. Nomura initiated coverage on shares of Sucampo Pharmaceuticals in a report on Monday, December 18th. They issued a “buy” rating and a $43.00 price objective for the company. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, December 7th. initiated coverage on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $14.00 target price for the company. BidaskClub upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Finally, Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Six investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $21.58.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 EPS.
In other news, insider Peter A. Kiener sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.13% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Krensavage Asset Management LLC increased its position in Sucampo Pharmaceuticals by 0.6% during the 2nd quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock worth $29,607,000 after purchasing an additional 16,570 shares in the last quarter. LSV Asset Management increased its position in Sucampo Pharmaceuticals by 1.9% during the 2nd quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock worth $25,099,000 after purchasing an additional 44,000 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $21,989,000. Vanguard Group Inc. increased its position in Sucampo Pharmaceuticals by 13.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock worth $17,287,000 after purchasing an additional 189,561 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock worth $16,487,000 after purchasing an additional 15,528 shares in the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.